ASCO guidance recommends Iressa
Executive Summary
American Society of Clinical Oncology recommends use of AstraZeneca's Iressa for treatment of non-small cell lung cancer in updated guidance published in 1Journal of Clinical Oncology. FDA approved Iressa (gefinitib) May 5 (2"The Pink Sheet" May 12, 2003, p. 7)...You may also be interested in...
Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains
Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: